Difference between revisions of "Edrecolomab (Panorex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Discontinued" to "Category:Discontinued drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 14: | Line 14: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-EpCAM antibodies]] | [[Category:Anti-EpCAM antibodies]] | ||
[[Category:EMA approved drugs]] | [[Category:EMA approved drugs]] | ||
[[Category:Discontinued drugs]] | [[Category:Discontinued drugs]] | ||
Revision as of 20:01, 27 February 2020
Mechanism of action
From the NCI Drug Dictionary: A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity.
Diseases for which it was used
Also known as
- Brand name: Panorex
History of changes in FDA indication
This medication was never approved by the FDA, but was the first monoclonal antibody approved for a cancer indication, in Germany (1995).